Ablation Versus Medical Management of Atrial Fibrillation in HFpEFLast updated on July 2021
- Recruitment Status
- Estimated Enrollment
- Same as current
- Atrial Fibrillation
- Heart Failure With Normal Ejection Fraction
- Not Applicable
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: 2:1 randomization to catheter ablation (PVI) or to medical management.Masking: Single (Outcomes Assessor)Masking Description: Serum biomarkers, atrial fibrillation burden, anatomical and functional echocardiographic parameters, and exercise capacity will all be measured and analyzed by study personnel blinded to the patient's intervention.Primary Purpose: Treatment
- Between 18 years and 90 years
- Both males and females
Recent studies using PVI for rhythm control in patients with heart failure with reduced ejection fraction (HFrEF) have shown improvement in systolic ejection fraction, exercise capacity, quality of life, and a significant reduction in all-cause mortality. The PVI procedure has been shown to be safe ...
Recent studies using PVI for rhythm control in patients with heart failure with reduced ejection fraction (HFrEF) have shown improvement in systolic ejection fraction, exercise capacity, quality of life, and a significant reduction in all-cause mortality. The PVI procedure has been shown to be safe and comparably effective in treating Atrial Fibrillation (AF) in HFpEF patients, but no studies have yet demonstrated the effects of catheter ablation on exercise capacity or clinical outcomes. The investigators propose a prospective, non-blinded randomized control pilot study to assess the feasibility of conducting larger scale studies to determine if there are differences between catheter ablation with medical management on exercise capacity and quality of life in HFpEF patients with AF. The investigators' study will be powered for AF burden reduction, and the investigators hope to use the effect size on exercise capacity and heart failure events to help determine power for larger clinical studies that will follow to shed light on how invasive management of atrial fibrillation may impact the natural history of individuals with these two cardiovascular conditions.
- NCT #
- Biosense Webster, Inc.
- Study Chair: Hugh Calkins, MD Johns Hopkins University Principal Investigator: David Spragg, MD Johns Hopkins University Study Director: Kavita Sharma, MD Johns Hopkins University